Ann: Investor Presentation, page-12

Trying to get some thoughts on this, as I do like what FTT is trying to acheive. Have been considering buying the dip after the crap raise.

In the Data quality from the pres, there are very few trial patients in the 51 to 100 pain score end. There are actually fewer than you would expect from the placebo cohort alone using Venus as a standard of care baseline IMO, let alone with 2/3rds actives included. So to me it looks like the placebo standard of care is producing far better outcomes that Venus.

Isn't there a risk that due to either a better standard of care, or due to sicker patients who have had no medical care at all (or self care?), and a re easier to improve (as the presentation says that there are very few drop outs - could it be these patients have few options), that we may be seeing a placebo group that is significantly outperforming expectations?

I've not done much research tbh - so not recommending anybody panic - lol - just asking!